Overview
Biote Q3 2025 revenue slightly beats analyst expectations at $48 mln
Net income for Q3 2025 decreased to $9.2 mln from $12.7 mln last year
Company repurchased approximately one mln shares of Class A common stock
Outlook
Biote reiterates 2025 revenue guidance above $190 mln
Company expects 2025 Adjusted EBITDA above $50 mln
2025 procedure revenue expected to decrease at high single-digit rate
Result Drivers
PROCEDURE REVENUE DECLINE - Procedure revenue fell 10.4%, offset by 8.4% growth in dietary supplements revenue
GROSS MARGIN IMPROVEMENT - Gross profit margin improved to 71.8% due to efficiencies from vertical integration and cost management
INCREASED EXPENSES - Operating income decreased due to higher expenses, including the shift of the annual provider conference
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $48 mln | $47.76 mln (5 Analysts) |
Q3 Adjusted EBITDA | $12.90 mln | ||
Q3 Gross Margin | 71.80% | ||
Q3 Adjusted EBITDA Margin | 26.90% | ||
Q3 Operating Income | $8.30 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the professional information services peer group is "buy"
Wall Street's median 12-month price target for Biote Corp is $5.46, about 47.6% above its November 4 closing price of $2.86
The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nBw3xRW9Ma
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)